We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A recent article and editorial in the Annals of Family Medicine criticizing direct-to-consumer (DTC) advertising prompted a strong rebuttal from industry groups.
A recent article and editorial in the Annals of Family Medicine criticizing direct-to-consumer (DTC) advertising prompted a strong rebuttal from industry groups.
Keeping up with state drug marketing laws will be a challenge for companies but should get easier with time as the laws become more uniform, industry experts said at an FDAnews audioconference.
An HIV/AIDS healthcare provider has filed a lawsuit against Pfizer, saying its marketing campaign for Viagra promoted recreational use of the drug and contributed to increased incidence of sexually transmitted diseases (STDs), including HIV.
A bipartisan group of lawmakers is using a recent government report to pressure the Bush administration to increase funding for FDA oversight of direct-to-consumer (DTC) drug advertising and to institute a moratorium on ads for newly approved products.
A bipartisan group of lawmakers is using a recent government report to pressure the Bush administration to increase funding for FDA oversight of direct-to-consumer (DTC) drug advertising and to institute a moratorium on ads for newly approved products.
The FDA is supporting a user fee program for direct-to-consumer (DTC) advertising, where companies are only required to pay when they have ads up for review, a high-ranking agency official told WDL.
The FDA is supporting a user fee program for direct-to-consumer (DTC) advertising, where companies are only required to pay when they have ads up for review, a high-ranking agency official told DID. Read More
The Democrats’ takeover of both houses of Congress will result in increased attention to the drug industry’s use of direct-to-consumer (DTC) advertising, but may not result in any real changes, industry observers say. Read More
The FDA’s tentative agreement with drug and biotechnology companies to accept fees in exchange for quicker reviews of direct-to-consumer (DTC) ads is prompting criticism from industry observers who believe the plan is both a conflict of interest and a violation of the First Amendment. Read More